[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352383-105":59,"doc-detail-352383-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","circulating-extracellular-vesicle-protein-biomarkers-for-the-early-detection-of-high-grade-serous-ovarian-cancer","Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer","","Small extracellular vesicles (sEVs) are emerging liquid biopsy biomarkers because their protein cargo reflects disease states. Plasma sEVs from a 70-sample case–control cohort were profiled using LC–MS/MS, enabling identification of circulating EV protein biomarkers that differentiate early-stage high-grade serous ovarian cancer from controls. Candidate biomarkers were selected based on fallopian tube lineage and STIC association and validated across tissues and EVs, supporting minimally invasive early detection while disease remains confined to the fallopian tube.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-extracellular-vesicle-protein-biomarkers-for-the-early-detection-of-high-grade-serous-ovarian-cancer/352383/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-extracellular-vesicle-protein-biomarkers-for-the-early-detection-of-high-grade-serous-ovarian-cancer/352383.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are the study’s primary goal and approach?","Question",{"text":113,"@type":114},"The study aims to identify circulating extracellular vesicle (EV) protein biomarkers for early detection of high-grade serous ovarian cancer. Plasma sEVs were analyzed using LC–MS/MS from a case–control cohort and followed by candidate validation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were candidate biomarkers selected and validated?",{"text":118,"@type":114},"Candidate biomarkers were prioritized based on fallopian tube origin and tissue expression in STIC lesions. They were validated using immunohistochemistry in fallopian tube and HGSOC tissues and Western blotting in fallopian tube/HGSOC cell-derived EVs, with additional immunoassay confirmation for selected proteins.",{"name":120,"@type":111,"acceptedAnswer":121},"Which biomarker panel showed diagnostic performance for early-stage disease?",{"text":122,"@type":114},"A four-protein combinatorial panel (MUC1, MYL6, TTYH3, and GSTP1) distinguished early-stage high-grade serous ovarian cancer from healthy controls, reporting an AUC of 0.975 and 90% sensitivity at 95% specificity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352383,1790146747,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer  \nAuthors  \nSagar Rayamajhi, Jared Sipes, Bidii Ngala, Amrita Mitra, Meizhang Li, Camille V. Trinidad, Wei Cui, Mohammod Mahmudur Rahman, Foyez Ahmmed, Leonidas E. Bantis, Mihaela E. Sardiu,  \nDennis W. Province, Harsh B. Pathak, and Andrew K. Godwin  \nCorrespondence Graphical Abstract  \n[agodwin@kumc.edu](agodwin@kumc.edu)  \nIn Brief  \nSmall extracellular vesicles (sEVs) are emerging liquid biopsy biomarkers that carry proteins reflective of disease states. Using LC–MS/MS to profile plasma sEVs from a 70-sample case–control cohort, we identified circulating EV protein biomarkers that distinguish early-stage high-grade serous ovarian cancer from controls. These candidate biomarkers highlight the potential of sEVproteomics to enable minimally invasive detection of high-grade serous ovarian cancer while the disease remains confined to the fallopian tube.  \n2026, Mol Cell Proteomics 25(2), 101508  \n© 2026 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license ([http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)).  \n[https://doi.org/10.1016/j.mcpro.2026.101508](https://doi.org/10.1016/j.mcpro.2026.101508)  \nHighlights  \n• LC–MS/MS custom spectral library–based circulating extracellular vesicle protein profile in highgrade serous ovarian cancer (HGSOC) .  \n• Fallopian tube–lineage and serous tubal intraepithelial carcinoma–associated upregulated extracellular vesicle protein profile in HGSOC.  \n• Candidate diagnostic biomarkers: MYL6, GSTP1, TTYH3, PRDX6, MUC1, MYH14, and PTGS1 .  \n• Combinatorial panel (MUC1, MYL6, TTYH3, and GSTP1) for detecting early-stage HGSOC.  \n RESEARCH  \n| Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer\u003Cbr>Sagar Rayamajhi 1 , Jared Sipes 1 ,2 , Bidii Ngala 1 , Amrita Mitra 1 , Meizhang Li 1, Camille V. Trinidad 1 ,3 , Wei Cui1 , Mohammod Mahmudur Rahman4 ,\u003Cbr>Foyez Ahmmed4 , Leonidas E. Bantis4, Mihaela E. Sardiu4, Dennis W. Province5 ,\u003Cbr>Harsh B. Pathak1 ,6, and Andrew K. Godwin 1 ,2 ,6 ,7 ,* |  |\n| --- | --- |\n| Small extracellular vesicles (sEVs), lipid-bilayer delimited particles (50–200 nm) released by cells, are emerging as a promising class of liquid biopsy biomarkers for elusive cancers, such as high-grade serous ovarian cancer (HGSOC). HGSOC originates from the fallopian tube (FT), progressing from p53 signatures to a precursor lesion known as serous tubal intraepithelial carcinoma (STIC). We hypothesize that sEVs contribute to ovarian cancer pathogenesis, carry cargo reflective of their site of origin, and serve as diagnostic biomarkers for early detection. To test this, we established a case–control cohort using archival plasma samples from 30 HGSOC patients (10 early stage [ES] and 20 late stage [LS]) and 40 healthy controls (HC). sEVs were enriched by size-exclusion chromatography and profiled by LC–MS/MS. Across all samples, 1078 EV-associated proteins (exoproteins) were identified, including 52 upregulated in ES HGSOC versus HC and 59 upregulated in LS HGSOC versus HCs (log2 fold change >1, p \u003C 0.05). Upregulated EV proteins were prioritized based on FT origin and tissue expression in STIC lesions. Seven candidate biomarkers (MYL6, GSTP1, TTYH3, PRDX6, MUC1, MYH14, and PTGS1) were validated by immunohistochemistry in FT tissue harboring STIC lesions and in HGSOC tissues, as well as by Western blotting in FT/HGSOC cell–derived EVs. These findings suggest that circulating exoproteins upregulated in ES cancer disease reflect precursor lesions. A four-protein combinatorial panel (MUC1, MYL6, TTYH3, and GSTP1), selected using Akaike Information Criterion, yielded an area under the curve (AUC) of 0.975 and 90% sensitivity at 95% specificity ","cbCaipxIxz1c1W0s","https://ap.wps.com/l/cbCaipxIxz1c1W0s","pdf",17664004,22,"English","# In Brief\n# Research\n# Introduction","[{\"question\":\"What are the study’s primary goal and approach?\",\"answer\":\"The study aims to identify circulating extracellular vesicle (EV) protein biomarkers for early detection of high-grade serous ovarian cancer. Plasma sEVs were analyzed using LC–MS/MS from a case–control cohort and followed by candidate validation.\"},{\"question\":\"How were candidate biomarkers selected and validated?\",\"answer\":\"Candidate biomarkers were prioritized based on fallopian tube origin and tissue expression in STIC lesions. They were validated using immunohistochemistry in fallopian tube and HGSOC tissues and Western blotting in fallopian tube/HGSOC cell-derived EVs, with additional immunoassay confirmation for selected proteins.\"},{\"question\":\"Which biomarker panel showed diagnostic performance for early-stage disease?\",\"answer\":\"A four-protein combinatorial panel (MUC1, MYL6, TTYH3, and GSTP1) distinguished early-stage high-grade serous ovarian cancer from healthy controls, reporting an AUC of 0.975 and 90% sensitivity at 95% specificity.\"}]","Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer | PDF",1790099292,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d44b9f0a259bf989703989f6262421f0.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f8573e786e56eafff0d4d02fb241737.webp",982,1294,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0a4c6cbad3880337cb37aa871347cd7.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5de03682a574d4e60830790049afec23.webp",980,1292]